Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 12/20 | 0.37 |
| ▸ | P2RX2 | Q9UBL9 | 12/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.33 |
| ▸ | PRNP | P04156 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22504228 | 0.82 | PIK3C3 (0.33) | TRPM8 | |
| SCHEMBL10566894 | 0.80 | KMT2A (0.47) | P2RX3P2RX2ALDH1A1L3MBTL1POLB | |
| SCHEMBL19523196 | 0.80 | P2RX3 (0.37) | P2RX3P2RX2ALDH1A1L3MBTL1TRPM8 | |
| SCHEMBL25910808 | 0.78 | P2RX3 (0.50) | P2RX3P2RX2 | |
| SCHEMBL10691443 | 0.78 | P2RX3 (0.36) | P2RX3P2RX2ALDH1A1POLB | |
| SCHEMBL30068102 | 0.78 | P2RX3 (0.50) | P2RX3P2RX2 | |
| SCHEMBL24943310 | 0.76 | P2RX3 (0.35) | P2RX3P2RX2ALDH1A1TRPM8MAPT | |
| SCHEMBL10630156 | 0.75 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL12447891 | 0.74 | APLNR (0.35) | ALDH1A1MAPT | |
| SCHEMBL2737354 | 0.74 | APLNR (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | KEAP1, NQO1, NFE2L2 | P2RX3 4602/4885P2RX2 4559/4885ALDH1A1 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.